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Abstract
This study investigated whether the new Global Multiple Sclerosis
Severity Scale (MSSS) correlated with cerebrospinal ﬂuid biomarkers
for axonal and glial pathology. The MSSS correlated with the phos-
phorylated neuroﬁlament heavy chain (NfH-SMI35, R=0.44, p=0.016).
The degree of neuroﬁlament phosphorylation (ratio NfH-SMI34 to
NfH-SMI35) was 8–fold higher in severely (median MSSS 6.5) ver-
sus mildly (MSSS 3.2) disabled patients (7.3 versus 0.9, p=0.03). The
MSSS may provide a statistically powerful tool for comparing overall
disease severity and be useful for validating the biomarker concept in
MS.MSSS and biomarker 3
Introduction
A new scale based on a statistical approach combining Kurtzke’s Expanded
Disability Status Scale score (EDSS) with historical databases has been
developed.1 This new scale, the Global Multiple Sclerosis Severity Score
(MSSS) aims to provide a measure for disease severity in an individual
patient on a cross–sectional basis. This has been achieved by providing
a statistically constructed look–up table of disease severity scores for pa-
tients with an EDSS between 0 and 9.5 and a disease duration between 1
to 30 years. This scale is potentially superior to the non–linear EDSS for
statistical evaluations, as it combines EDSS and disease duration in one
variable that is normally distributed.
Biomarkers for axonal degeneration, such as neuroﬁlaments and glial
scar tissue, such as glial ﬁbrillary acidic protein (GFAP) have previously
been related to disability and prognosis.2–6 There is supporting evidence
from animal and cell–culture work that levels of phosphorylated neuroﬁla-
ments correlate with the loss of axons and function.7–9
Here we investigate for the ﬁrst time (1) whether the newly developed
Global MSSS correlates with biomarkers for axonal degeneration (neuroﬁl-
aments), glial activation (S100B) and astrogliosis (GFAP), and (2) whether
these biomarker levels are higher in those patients with more severe dis-
ease as deﬁned by the Global MSSS.
Patients and methods
Data from a previously published cohort of 29 patients with clinically def-
inite MS in whom a 3–year follow–up cerebrospinal ﬂuid (CSF) sample
was available10 was reanalyzed. The demographic data, representing theMSSS and biomarker 4
current disease course, is summarised in the result section. All analyses
were based on this follow–up visit.
The phosphorylated neuroﬁlament heavy chain (NfHSMI35 ), the hyper-
phosphorylated neuroﬁlament heavy chain (NfHSMI34 ), glial ﬁbrillary acidic
protein (GFAPSMI26 ), S100B and ferritin were quantiﬁed as described.3,10
The phosphoform ratio (RATIO =
NfH SMI34
NfH SMI35  10) was used to estimate the
degree of phosphorylation, with higher values indicating a higher degree
of NfH phosphorylation. Samples of CSF were obtained by routine lumbar
puncture. Aliquots of CSF were stored at -70◦C until assayed.
The EDSS was recorded as described,11 the progression index was
calculated as the ratio of the EDSS to disease duration and the Global
MSSS was taken from Figure 3 from the paper by Roxburgh and col-
leagues.1 The progression index was calculated as the EDSS divided by
the disease duration.
Data analysis The linear relationship between continuous variables was
evaluated using the Spearman correlation coefﬁcient. We were interested
testing whether previously reported correlations of biomarkers with dis-
ability scales (NfHSMI35 , GFAP and S100B2,3) would be repeated for the
MSSS. The Bonferroni corrected level of signiﬁcance ( = 0:05) for these
three comparisons calculates to p0.016. The non–parametric Kruskal–
Wallis test was used to compare CSF biomarker levels between patients
with mild disease course versus those with a severe disease course ac-
cording to a previously–used cut–off value of an MSSS of 4.8.12 All com-
parisons were made using SAS software (version 8.2).MSSS and biomarker 5
Results
There were 14 female and 15 male patients with a median age of 46.3
(range 28.5–64.8) years, a median disease duration of 13 (range 3.1–27.6)
years and a median relapse–free interval of 24 (range 0.7–270.5) months.
The results for the CSF axonal and glial biomarker levels are sum-
marised in Table 1. Patients with a more severe disease course had an
8–fold higher NfH phosphoform ratio (7.3 versus 0.9, p=0.033), indicat-
ing a higher degree of NfH phosphorylation in these patients (Table 1).
In contrast, the estimation of disease severity based on the EDSS alone
using our previously–published cut–off limit3 of 6.5 did not reveal such a
difference (data not shown).
The CSF NfHSMI35 levels correlated with the MSSS (R=0.44, p=0.016,
Figure 1). No such correlation was found for either CSF GFAP or CSF
S100B levels with the MSSS (p=0.81, p=0.39, respectively).
The Global MSSS correlated with the progression index (R=0.8, p<0.0001).
However, when we repeated above analyses using the progression index
instead of the Global MSSS, we were not able to show any of above corre-
lations, nor was there a difference between disease severity groups (data
now shown).
Discussion
The ﬁnding of a signiﬁcant, 8-fold increased degree of NfH phosphoryla-
tion, but not of NfHSMI35 and NfHSMI34 alone, in patients with a more severe
disease course on the Global MSSS is interesting. There is a body of evi-
dence from the dementia and motoneuron literature for an increase of NfH
phosphorylation (reviewed in2). Using a different approach we have pre-MSSS and biomarker 6
viously demonstrated that NfH phosphorylation may increase during the
progressive phase of MS.10 Our previous results were based on the classi-
ﬁcation of MS patients into those with a relapsing remitting (RR) and those
with a secondary or primary progressive (SP/PP) disease course.13 The
more convincing ﬁnding of a 8–fold difference using the MSSS1 versus an
about 2–fold difference using the traditional classiﬁcation13 suggests that
disease severity and NfH phosphorylation may be related and independent
of the clinical phenotype (i.e. RR versus SP/PP).
The ﬁnding that the strength of the correlation between the CSF NfHSMI35 was
marginally better with the EDSS (R=0.54) [see reference10] compared to
the Global MSSS (R=0.44) in this analysis can be explained by com-
paring Figure 1 with Figure 2A in reference.10 One patient with CSF
NfHSMI35 levels of 402 pg/mL, an EDSS of 4 and a disease duration of
21.8 years corresponding to a Global MSSS of 2.53. This patient appears
as the outlier in Figure 1. Based on other studies on relapsing MS (re-
viewed in2) one could make the argument that the CSF NfHSMI35 levels
could be related to relapses, but we do not believe this to be the case as
the last relapse was 72.9 months ago and CSF neuroﬁlament levels are
known to plateau out within 3 months following a relapse.6 It is of note
that a number of patients with patients with severe disease, i.e. a high
MSSS, had non–detectable CSF NfHSMI35 levels. One possible explana-
tion is that axonal degeneration had already occurred a long time ago and
biochemical evidence for the damage has been washed out from the CSF.
Another possibility is that these patients may have suffered predominantly
from cortical damage, which may not necessarily be reﬂected in lumbar
CSF, because of the CSF ﬂow dynamics.
We were not able to demonstrate a correlation between the MSSS andMSSS and biomarker 7
the glial biomarkers GFAP and S100B. This ﬁnding contrasts with previ-
ous reports which showed a correlation between disability scales and CSF
GFAP levels.3–5 The reason for this is likely to be similar to the arguments
made above for non–detectable CSF NfHSMI35 levels.
The authors of the Global MSSS highlighted that the difﬁculty in as-
sessing disability is partly caused by the random damage to more or less
relevant anatomical pathways.1 Some of this damage will be caused by
demyelination and conduction block which may resolve. It seems plausi-
ble to assume that the occasional functional recovery, even after a struc-
tural deﬁcit (i.e. deﬁnite axonal loss) may at least in part be due to central
adaption or neuronal plasticity.
Taking this together the Global MSSS appears to be a statistically more
powerful tool for comparing overall disease severity than the progression
index, and should be evaluated alongside the EDSS in the future studies
needed to validate the biomarker concept in MS.
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Table 1: Cerebrospinal ﬂuid biomarker levels in MS
patients according to disease severity on the Global
MSSS. The median (IQR) are shown.
MS Disease severity
(all) mild severe
MSSS 4.6 (3.1-6.5) 3.1 (2.8-4.1) 6.9 (5.2-7.5)∗
NfHSMI34 pg/mL 50 (9-129) 17 (0-68) 77 (30-204)
NfHSMI35 pg/mL 113 (0-178) 96 (0-198) 135 (0-223)
Ratio 3 (1-10.1) 0.9 (0.5-3.9) 7.3 (2.1-13.4)†
S100B ng/mL 0.44 (0.35-0.53) 0.44 (0.35-0.55) 0.44 (0.34-0.51)
GFAPSMI26 pg/mL 5 (4-7) 4 (4-7) 5 (4-8)
Ferritin ng/mL 6 (5-7) 6 (6-7) 6 (5-6)
p<0.0001 for mild versus severe
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Figure 1: Correlation between the MSSS and CSF NfHSMI35 levels.